Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 Mutation

To evaluate the efficacy and safety of Genetic subtype-matched targeted therapy in the treatment of treatment-naive diffuse large B-cell lymphoma with TP53 mutation.

Trial Details

NCT ID
NCT07499271
Phase
PHASE2
Sponsor
The First Affiliated Hospital of Soochow University
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • POLA-R-CHP
  • Orelabrutinib
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Patients aged 18 years and older, up to 70 years.
  • Participants must be able to understand and willing to sign the written informed consent form.
  • Eastern Cooperative Oncology Group performance status 0 to 3.
  • Life expectancy ≥3 months (as determined by the investigator).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →